Physician profile
Daniel E Laeupple
NPI 1669420865
$7,245.24
in general payments reported to CMS, 2019-2025
30 companies · $564 in 2025
The $564 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $991 · 2021: $1,176 · 2022: $992 · 2023: $1,347 · 2024: $1,247 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,157.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,200.55 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $854.89 | 2019-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $530.98 | 2019-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $491.43 | 2019-2023 | Trintellix |
| Axsome Therapeutics, INC. | $442.03 | 2022-2025 | Auvelity, Sunosi |
| Almatica Pharma LLC | $429.58 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Vanda Pharmaceuticals INC. | $332.91 | 2019-2024 | Fanapt |
| Sunovion Pharmaceuticals INC. | $331.43 | 2020-2021 | |
| Corium, LLC | $295.59 | 2022-2025 | Azstarys |
| Lundbeck LLC | $288.06 | 2019-2024 | Rexulti |
| Alkermes, INC. | $280.30 | 2019-2025 | Aristada, Lybalvi |
| Bausch Health US, LLC | $203.73 | 2019-2024 | Aplenzin, Wellbutrin |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $179.96 | 2020-2025 | Caplyta |
| Allergan, INC. | $175.47 | 2019-2021 | |
| Neos Therapeutics, Lp | $168.77 | 2019-2024 | Adzenys Xr-Odt |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $133.38 | 2019-2025 | Austedo Xr, Austedo Xr |
| Eisai INC. | $122.02 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $107.55 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $106.90 | 2023-2025 | Quviviq, Quviviq |
| Ironshore Pharmaceuticals INC. | $103.03 | 2019-2024 | |
| Tris Pharma INC | $100.83 | 2022-2023 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $86.66 | 2020-2023 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $56.48 | 2022-2023 | Qelbree |
| Merck Sharp & Dohme LLC | $53.53 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $44.35 | 2019 | |
| Adlon Therapeutics L.P. | $37.25 | 2019-2021 | |
| Neuronetics, INC. | $33.34 | 2019 | |
| Shire North American Group INC | $20.60 | 2019 | |
| Orexo US, INC. | $18.26 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Laeupple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.